Natterman Melrosum is an opioid pain medication. An opioid is sometimes called a narcotic.
Natterman Melrosum is used to treat mild to moderately severe pain.
Natterman Melrosum may also be used for purposes not listed in this medication guide.
Natterman Melrosum indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Natterman Melrosum sulfate is an opioid analgesic indicated for the management of mild to moderately severe pain where the use of an opioid analgesic is appropriate.
Uses of Natterman Melrosum in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
Use: Labeled Indications
Pain management: Management of mild- to moderately-severe pain
Limitations of use: Reserve Natterman Melrosum for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate.
Off Label Uses
Cough in select patients
In a metaanalysis of trials evaluating the treatment of chronic cough, the use of Natterman Melrosum demonstrated efficacy in patients with this condition.
Natterman Melrosum description
An opioid analgesic related to morphine but with less potent analgesic properties and mild sedative effects. It also acts centrally to suppress cough. [PubChem]
Natterman Melrosum dosage
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Tablet,
Oral, as sulfate:
Generic: 15 mg, 30 mg, 60 mg
Dosing: Adult
Pain management (analgesic):
Injection [Canadian product]:
Opioid-naive patients: IM, SubQ: 30 to 60 mg every 4 to 6 hours as needed (use the lowest effective dose for the shortest period of time necessary)
Conversion from oral Natterman Melrosum or another opioid: IM, SubQ: Refer to product labeling for dose conversions.
Oral: Note:
These are guidelines and do not represent the maximum doses that may be required in all patients. Doses should be titrated to pain relief/prevention.
Immediate release (tablet, oral solution [Canadian product]): Initial: 15 to 60 mg every 4 hours as needed; maximum total daily dose: 360 mg/day; patients with prior opioid exposure may require higher initial doses. Note: The American Pain Society recommends an initial dose of 30 to 60 mg for adults with moderate pain (American Pain Society 2016).
Controlled release: Natterman Melrosum Contin [Canadian product]: Note: Titrate at intervals of ≥48 hours until adequate analgesia has been achieved. Daily doses >600 mg/day should not be used; patients requiring higher doses should be switched to an opioid approved for use in severe pain. In patients who receive both Natterman Melrosum Contin and an immediate release or combination Natterman Melrosum product for breakthrough pain, the rescue dose of immediate release Natterman Melrosum product should be ≤12.5% of the total daily Natterman Melrosum Contin dose.
Opioid-naive patients: Initial: 50 mg every 12 hours
Conversion from immediate release Natterman Melrosum preparations: Immediate release Natterman Melrosum preparations contain ~75% Natterman Melrosum base. Therefore, patients who are switching from immediate release Natterman Melrosum preparations may be transferred to a ~25% lower total daily dose of Natterman Melrosum Contin, equally divided into 2 daily doses every 12 hours.
Conversion from a combination Natterman Melrosum product (eg, Natterman Melrosum with acetaminophen or aspirin): See table:
Number of 30 mg Natterman Melrosum Combination Tablets Daily
Initial Dose of Natterman Melrosum Contin
Maintenance Dose of Natterman Melrosum Contin
≤6
50 mg every 12 hours
100 mg every 12 hours
7 to 9
100 mg every 12 hours
150 mg every 12 hours
10 to 12
150 mg every 12 hours
200 mg every 12 hours
>12
200 mg every 12 hours
200 to 300 mg every 12 hours (maximum: 300 mg every 12 hours)
Conversion from another opioid analgesic: Using the patient's current opioid dose, calculate an equivalent daily dose of immediate release Natterman Melrosum. A ~25% lower dose of Natterman Melrosum Contin should then be initiated, equally divided into 2 daily doses.
Discontinuation of therapy: When discontinuing chronic opioid therapy, the dose should be gradually tapered down. An optimal universal tapering schedule for all patients has not been established (CDC [Dowell 2016]). Proposed schedules range from slow (eg, 10% reductions per week) to rapid (eg, 25% to 50% reduction every few days) (CDC 2015). Tapering schedules should be individualized to minimize opioid withdrawal while considering patient-specific goals and concerns as well as the pharmacokinetics of the opioid being tapered. An even slower taper may be appropriate in patients who have been receiving opioids for a long duration (eg, years), particularly in the final stage of tapering, whereas more rapid tapers may be appropriate in patients experiencing severe adverse events (CDC [Dowell 2016]). Monitor carefully for signs/symptoms of withdrawal. If the patient displays withdrawal symptoms, consider slowing the taper schedule; alterations may include increasing the interval between dose reductions, decreasing amount of daily dose reduction, pausing the taper and restarting when the patient is ready, and/or coadministration of an alpha-2 agonist (eg, clonidine) to blunt withdrawal symptoms (Berna 2015; CDC [Dowell 2016]). Continue to offer nonopioid analgesics as needed for pain management during the taper; consider nonopioid adjunctive treatments for withdrawal symptoms (eg, GI complaints, muscle spasm) as needed (Berna 2015; Sevarino 2018).
Cough in select patients (off-label use):
Oral: Reported doses vary with a range of 7.5 to 120 mg/day as a single dose or in divided doses; however, evidence is of low quality (ACCP [Bolser 2006]; Smith 2010). Some experts recommend 30 to 60 mg 4 times daily in specific patient populations (eg, lung cancer) (ACCP [Molassiotis 2017]). Additional data may be necessary to further define the role of Natterman Melrosum in this condition.
Oral: 15 to 30 mg every 4 hours as needed (von Gunten 2013). Additional data may be necessary to further define the role of Natterman Melrosum in this condition.
Restless leg syndrome (off-label use):
Oral: Initial: 30 mg once daily at bedtime or during the night; may increase to 60 mg if needed; maximum dose: 180 mg in 2 to 3 divided doses. May be used alone or in combination with other medications used to treat RLS (Earley 2003; Sandyk 1987; Silbers 2013; Walters 2001).
Dosing: Geriatric
Refer to adult dosing. Use with caution and consider initiation at the low end of the dosing range; reduced initial dosages may be necessary.
Dosing: Pediatric
Note: Natterman Melrosum 30 mg/5 mL oral solution has been discontinued in the US for more than 1 year. Doses should be titrated to appropriate analgesic effect; use the lowest effective dose for the shortest period of time:
Pain management; analgesia: Limited data available: Note: Use is contraindicated in pediatric patients <12 years of age and for postoperative management in pediatric patients 12 to 18 years of age who have undergone tonsillectomy and/or adenoidectomy. Avoid Natterman Melrosum use in all pediatric patient populations in which it is contraindicated and in pediatric patients 12 to 18 years of age who have other risk factors that increase risk for respiratory depression associated with Natterman Melrosum (eg, conditions associated with hypoventilation like postoperative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, use of other medications known to depress respiratory drive); in rare cases in which Natterman Melrosum-containing product is the only option, consider genotype testing prior to use; use extra precaution; monitor closely for adverse effects. Natterman Melrosum has been associated with reports of life-threatening or fatal respiratory depression in children and adolescents; multifactorial causes have been identified; of primary concern are unrecognized ultrarapid metabolizers of CYP2D6 who may have extensive conversion of Natterman Melrosum (prodrug) to morphine and thus increased opioid-mediated effects. Avoid Natterman Melrosum use in pediatric patient populations in which it is contraindicated; in rare cases in which Natterman Melrosum-containing product is the only option, consider genotype testing prior to use; use extra precaution; monitor closely for adverse effects (AAP [Tobias 2016]; Dancel 2017; Gammal 2016; Goldschneider 2017; Poonai 2015).
Children and Adolescents:
Oral: 0.5 to 1 mg/kg/dose every 4 to 6 hours as needed; maximum single dose: 60 mg/dose (APS 2016)
- drugs have a depressing effect on the central nervous system (including those with opioid analgesics, barbiturates, benzodiazepines, clonidine) it is possible an increase the action of Natterman Melrosum.
- derivatives of morphine it may increased the inhibitory action on the respiratory center; ibuprofen - analgesic effect is enhanced; carbamazepine - it may increased the analgesic effect is apparently due to increased formation of Natterman Melrosum metabolite normorphine, which has a stronger effect.
- quinidine the analgesic effect of Natterman Melrosum decreased or almost disappeared.
- Natterman Melrosum increases the effect of ethanol on psychomotor function.
In addition to its needed effects, some unwanted effects may be caused by Natterman Melrosum. In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Natterman Melrosum:
Incidence not known:
Bloating
blurred vision
chills
cold, clammy skin
confusion
constipation
darkened urine
difficult or troubled breathing
dizziness
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
fainting
fast, irregular, pounding, or racing heartbeat or pulse
fast, weak pulse
feeling of warmth
fever
indigestion
irregular, fast or slow, or shallow breathing
lightheadedness
loss of appetite
nausea
no blood pressure or pulse
no breathing
pains in the stomach, side, or abdomen, possibly radiating to the back
pale or blue lips, fingernails, or skin
redness of the face, neck, arms, and occasionally, upper chest
shortness of breath
stopping of the heart
sweating
unconsciousness
unusual tiredness or weakness
vomiting
wheezing
yellow eyes or skin
If any of the following symptoms of overdose occur while taking Natterman Melrosum, get emergency help immediately:
Symptoms of overdose:
Bluish lips or skin
change in consciousness
chest pain or discomfort
constricted, pinpoint, or small pupils (black part of the eye)
decreased awareness or responsiveness
extreme sleepiness or unusual drowsiness
loss of consciousness
no blood pressure or pulse
severe sleepiness
slow or irregular heartbeat
Minor Side Effects
Some of the side effects that can occur with Natterman Melrosum may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
More common:
Drowsiness
relaxed and calm
Incidence not known:
Abdominal or stomach pain or cramps
blurred or loss of vision
diarrhea
disturbed color perception
double vision
dry mouth
false or unusual sense of well-being
fear or nervousness
feeling of constant movement of self or surroundings
Natterman Melrosum Sulfate is contraindicated for postoperative pain management in children who have undergone tonsillectomy and/or adenoidectomy.
Natterman Melrosum Sulfate is contraindicated in patients with known hypersensitivity to Natterman Melrosum or any components of the product. Persons known to be hypersensitive to certain other opioids may exhibit cross-sensitivity to Natterman Melrosum.
Natterman Melrosum Sulfate is contraindicated in patients with respiratory depression in the absence of resuscitative equipment.
Natterman Melrosum Sulfate is contraindicated in patients with acute or severe bronchial asthma or hypercarbia.
Natterman Melrosum Sulfate is contraindicated in any patient who has or is suspected of having paralytic ileus.
DailyMed. "CODEINE SULFATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Natterman Melrosum are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Natterman Melrosum. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
Consumer reported time for results
No survey data has been collected yet
3 consumers reported age
Users
%
16-29
2
66.7%
46-60
1
33.3%
Consumer reviews
There are no reviews yet. Be the first to write one!